Details related to the Envisia presentation are as follows:
Monday, October 17, 2016
Poster #PO410: Interim 3-Month Safety and Efficacy Evaluation of Low-Dose Intracameral ENV515 Travoprost XR in 12-Month Study in Glaucoma Patients
- McCormick Place, South Hall A, 12:30pm – 2:00 pm, Monday, October 17, 2016
- Presented by Dr. Thomas R. Walters, MD, Austin, TX
ENV515 is a fully biodegradable PRINT-particle formulation of a marketed prostaglandin analog that has the potential to lower intraocular pressure (IOP) for more than 6 months from a single dose. ENV515 was designed to address the issue of poor patient compliance that exists today with daily eye drops and limit the progression of glaucoma that sometimes leads to vision loss. Envisia is also leveraging the Company's unique platform technology to develop products for other leading ocular diseases, including age-related macular degeneration (AMD) and diabetic macular edema (DME).
ABOUT ENVISIA THERAPEUTICS™
Envisia Therapeutics is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology platform to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, extended-release formulation of a marketed prostaglandin analogue with the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is actively exploring the use of the company's unique technology to develop products for other important ocular diseases including age-related macular degeneration (AMD) and diabetic macular edema (DME). Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/envisia-therapeutics-to-present-at-aao-2016-annual-meeting-300345432.html
SOURCE Envisia Therapeutics